Sutro Biopharma (STRO) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Protara Therapeutics (TARA) over the past year, gaining 2.4% versus a loss of 68.6%. Over five years, TARA leads with a -67.8% price change compared with -94.7% for STRO. Sutro Biopharma is the larger company by market cap ($142.8 million vs $140.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | STRO | TARA |
|---|---|---|
| Share price | $8.60 | $2.28 |
| Market cap | $142.77M | $140.38M |
| 1-day change | -1.38% | -5.00% |
| YTD return | -25.67% | -57.22% |
| 1-year return | +2.38% | -68.60% |
| 5-year return | -94.68% | -67.80% |
| EPS (TTM) | $-12.42 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $102.48M | — |
| Revenue growth (YoY) | +65.18% | — |
| Net income (latest FY) | $-191.09M | $-57.44M |
| Operating margin | -154.53% | — |
| Net margin | -186.45% | — |
| 52-week high | $43.85 | $7.82 |
| 52-week low | $7.15 | $2.09 |
| Distance from 52-week high | -80.39% | -70.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +419.65% | +1010.96% |
| Average volume | 304.90K | 1.07M |
| Shares outstanding | 16.60M | 61.57M |
| Employees | 129 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed TARA by 71.0 percentage points over the past year.
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
STRO vs TARA FAQ
Which is bigger, Sutro Biopharma or Protara Therapeutics?
Sutro Biopharma (STRO) is larger, with a market capitalization of $142.77M compared with $140.38M for Protara Therapeutics (TARA).
Which stock has performed better over the past year, STRO or TARA?
STRO returned +2.38% over the past 12 months, compared with -68.60% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Sutro Biopharma and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.